Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG known ✓ | Q16739 | 3/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 18/20 | 1.00 |
| ▸ | GBA1 | P04062 | 7/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | MGAM | O43451 | 2/20 | 1.00 |
| ▸ | SI | P14410 | 2/20 | 1.00 |
| ▸ | AGL | P35573 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miglustat SCHEMBL7911410 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL19627563 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL6821044 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL19075917 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL7911243 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL7908063 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL23503067 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20577242 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20576705 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20769803 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306058-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-04-19 | — | — | US | claimed |
| WO-2017201052-A1 | METHODS OF TREATING ZIKA VIRUS INFECTION | EMERGENT VIROLOGY LLC (US) | 2017-11-23 | — | — | WO | claimed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | claimed |
| EP-4626464-A1 | FEXAMETHODS FOR TREATING INFANTILE-ONSET POMPE DISEASE IN PEDIATRIC PATIENTS | Amicus Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626465-A1 | METHODS FOR TREATING LATE ONSET POMPE DISEASE IN PEDIATRIC PATIENTS | Amicus Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4518885-A1 | METHODS FOR TREATING POMPE DISEASE | Amicus Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-109196097-B | Method for selecting high M6P recombinant proteins | 阿米库斯治疗学公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024119091-A1 | FEXAMETHODS FOR TREATING INFANTILE-ONSET POMPE DISEASE IN PEDIATRIC PATIENTS | AMICUS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024119070-A1 | METHODS FOR TREATING LATE ONSET POMPE DISEASE IN PEDIATRIC PATIENTS | AMICUS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-3871688-B1 | DOSING REGIMENS FOR THE TREATMENT OF POMPE DISEASE | AMICUS THERAPEUTICS INC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4291225-A1 | RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE AND USES THEREOF | Amicus Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20090111812-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111812-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-04-30 | — | — | US | disclosed |
| US-20070270350-A1 | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270350-A1 | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2007-11-22 | — | — | US | disclosed |
| EP-0624652-B1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO CO (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1132370-A2 | Process for producing n-substituted polyhydroxy nitrogen-containing heterocyles | MONSANTO COMPANY (US) | 2001-09-12 | — | — | EP | disclosed |
| US-5695969-A | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| US-5401645-A | Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium | MONSANTO COMPANY (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0624652-A1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO COMPANY (US) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270350-A1 | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions | HMGCR, GCKR, GSR | UGCG 37/4885GBA2 898/4885GBA1 430/4885 |
| US-11306058-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | MGAM, UGCG, UGDH | UGCG 2/4885GBA2 99/4885GBA1 53/4885 |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | UGCG 12/4885GBA2 4/4885GBA1 1/4885 |
| US-20090111812-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS | IL1B, IL1A, NOS2 | UGCG 2593/4885GBA2 3061/4885GBA1 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.